checkAd
    Startseite > Aktien > Verastem > Nachrichten

    Neueste Nachrichten

    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
    07.06.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    24.05.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
    23.05.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    09.05.24 · Business Wire (engl.) · Verastem
    Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    07.05.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    18.04.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.04.24 · Business Wire (engl.) · Verastem
    Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
    18.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    14.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
    11.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
    05.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
    05.03.24 · Business Wire (engl.) · Verastem